Overview of the Breakthrough
Immorta Bio Inc. has announced a major longevity science milestone. The Miami-based biotechnology company revealed breakthrough preclinical results from aging mouse models. Its novel dual-platform therapy produced dramatic lifespan extension. Furthermore, the American Association of Immunologists (AAI) accepted the research for presentation at IMMUNOLOGY2026.
Consequently, this announcement positions Immorta Bio as a frontrunner in longevity therapeutics. The company focuses on two core objectives: Treating Diseases of Aging and Treating Aging as Disease™.
The Dual-Platform Therapy Explained
SenoVax™: Senolytic Immunotherapy
SenoVax™ is Immorta Bio’s first-in-class senolytic immunotherapy. It trains the immune system to find and destroy senescent cells. These so-called “zombie” cells accumulate with age. Moreover, they drive chronic inflammation, tissue dysfunction, and age-related disease. SenoVax™ targets and clears these harmful cells selectively.
StemCellRevivify™: Regenerative Stem Cell Platform
The StemCellRevivify™ platform complements SenoVax™ directly. It generates personalized mesenchymal stem cells (pMSCs) through cellular rejuvenation technology. As a result, it restores the body’s declining regenerative capacity. Together, both platforms address the two root drivers of biological aging.
Why the Combination Matters
Aging progresses through two distinct biological processes. First, senescent cells accumulate and damage surrounding tissue. Second, the body loses its ability to repair that damage over time. Therefore, addressing only one process leaves the other unchecked. Immorta Bio’s dual approach tackles both simultaneously — a key differentiator in the longevity field.
Key Preclinical Results
The preclinical studies used validated murine aging models. The findings were striking. Treated animals showed approximately 73% increase in mean survival over untreated controls. Additionally, the therapy produced roughly 84% extension of median lifespan.
Beyond raw survival data, treated animals also showed meaningful healthspan improvements, including:
- Enhanced physical performance
- Reduced frailty markers
- Better overall functional outcomes
Thus, the therapy does not merely extend life — it extends healthy, functional life.
Disease Model Findings
Immorta Bio also ran separate disease-model studies. One key study used carbon tetrachloride (CCl₄)-induced liver injury. The combination therapy demonstrated significant regenerative effects in these animals. Organ function improved markedly. This finding supports the platform’s broader potential across multiple age-related conditions — not just aging itself, but organ failure and liver disease specifically.
Presentation at IMMUNOLOGY2026
The AAI Annual Meeting runs from April 15–19, 2026, in Boston, Massachusetts. It is among the world’s leading international conferences for immunology research. Immorta Bio’s acceptance for presentation there underscores the scientific credibility of its work. Notably, this follows the company’s prior presentation of preclinical oncology data at the 2025 AAI meeting.
The company’s research additionally received attention from the longevity podcast Life Sciences News. Importantly, that episode was produced independently, without participation or sponsorship from Immorta Bio.
Leadership Statements
Chief Scientific Officer’s Perspective
Dr. Thomas Ichim, President and Chief Scientific Officer, emphasized the novelty of the approach. “By combining immune-mediated clearance of senescent cells with regenerative cell therapy, we aim to address both the damage caused by aging and the decline in the body’s ability to repair itself,” he said.
Chairman and CEO’s Vision
Dr. Boris Reznik, Chairman and CEO, highlighted the broader implications. He noted that the results validate Immorta Bio’s founding vision. The company now advances rapidly toward IND-enabling studies for human clinical trials. Its initial focus targets devastating age-related conditions such as liver disease and cancer.
